Next generation hybrid nanomaterials: bispecific antibody-targeted polymers

该项目旨在开发和优化一种新的平台技术，以帮助开发由纳米材料和生物分子组成的混合材料，这些材料构成了许多商业诊断设备的基础。一种新型抗体MIL38将为该技术提供测试平台，该技术旨在提供一种在生理条件下稳定的平台，并使纳米材料与抗体易于结合。该项目有可能快速改善合成纳米材料和生物制剂之间的连接过程，从而更有效地合成靶向诊断。这将为该领域开发的任何纳米材料提供显着的商业优势，特别是对于该项目，加快MIL38的翻译。

This project aims to develop and optimise a novel platform technology that will assist in the development of hybrid materials consisting of nanomaterials and biomolecules, which form the basis of many commercial diagnostic devices. A novel antibody, MIL38, will provide the test bed for the technology, which will aim to deliver a platform that is stable under physiological conditions and that enables facile conjugation of nanomaterials with antibodies. This project has the potential to rapidly improve the ligation process between synthetic nanomaterials and biologics, leading to more efficient synthesis of targeted diagnostics. This would provide a significant commercial advantage for any nanomaterials developed for the field, and specifically for this project, expedite translation of MIL38.